SILK News and Press, Silk Road Medical Inc. From 05/02/22

Medical device company, Silk Road Medical (NASDAQ:SILK) announced on Monday that the U.S. Food and Drug Administration (FDA) expanded the approval for its Enroute stent to include patients who are at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the Enroute s...

SUNNYVALE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded indications for t...

SUNNYVALE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2022 Healthcare Conference. Managemen...

SUNNYVALE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022...

Silk Road Medical has seen its premium valuation come down quite a bit over the past year. This pullback was welcome, as Silk appears to be a secular winner here. I am a bit more reserved after a big recovery in recent weeks. Upon further declines, or a retest of the lows, I a...

The following slide deck was published by Silk Road Medical, Inc in conjunction with their 2021 Q4 earnings call. For further details see: Silk Road Medical, Inc 2021 Q4 - Results - Earnings Call Presentation

Silk Road Medical, Inc (SILK) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Erica Rogers - Chief Executive Officer Lucas Buchanan - Chief Financial Officer and Chief Operating Officer Conference Call Participants Joanne Wuen...

Silk Road Medical press release (NASDAQ:SILK): Q4 GAAP EPS of -$0.42 misses by $0.07. Revenue of $28.3M (+33.9% Y/Y) beats by $2.39M. Shares +7.7%. For further details see: Silk Road Medical GAAP EPS of -$0.42 misses by $0.07, revenue of $28.3M beats by $2.39M

SUNNYVALE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2021. “Our team and p...

SUNNYVALE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday...